Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CohBar Inc CWBR

Healthcare Biotechnology
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to... see more

Recent & Breaking News (GREY:CWBR)

CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

GlobeNewswire March 12, 2021

CohBar to Present at the 33rd Annual ROTH Conference

GlobeNewswire March 2, 2021

CohBar to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire February 25, 2021

CohBar to Present at the BIO CEO & Investor Digital Conference

GlobeNewswire February 9, 2021

CohBar to Present at the 3rd Annual Longevity Therapeutics Conference

GlobeNewswire January 20, 2021

CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

GlobeNewswire January 11, 2021

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

GlobeNewswire December 9, 2020

CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

GlobeNewswire November 19, 2020

CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 16, 2020

CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

GlobeNewswire November 2, 2020

CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire October 29, 2020

CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

GlobeNewswire October 27, 2020

CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

GlobeNewswire October 26, 2020

CohBar to Present at the BIO-Europe Conference

GlobeNewswire October 15, 2020

CohBar's CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

GlobeNewswire October 8, 2020

CohBar to Present at the BIO Investor Forum

GlobeNewswire October 5, 2020

CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

GlobeNewswire September 29, 2020

CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

GlobeNewswire September 10, 2020

CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 3, 2020

CohBar Announces Closing of Public Offering of Common Stock and Warrants

GlobeNewswire August 28, 2020